BCC
Conditions
Keywords
BCC
Brief summary
This study is single-arm, none randomized, open label, two-dose-cohorts, single center clinical trial for evaluation of the safety and efficacy of Oshadi D and Oshadi R in patients with BCC. Patients will receive Oshadi D and Oshadi R for 60 -90 days until the planned surgical excision of the lesion.
Interventions
DRUGOshadi D & Oshadi R
Anti tumor agents
Sponsors
Oshadi Drug Administration
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 21 years old with tissue confirmed diagnosis of local BCC. * Patient is candidate for surgical excision of the BCC in few months. * BCC lesion ≥10mm in its longest diameter. * Sexually active fertile patients and their partners must agree to use medically accepted methods of contraception during therapy and 3 months after the last dose of the study drugs. * Female patients of childbearing potential must have a negative pregnancy test at screening. * Patient must understand and be willing to give written informed consent prior to any study procedures or evaluations and be willing to adhere to all study schedules and requirements.
Exclusion criteria
* Uncontrolled Intercurrent illness or any history of significant cardiac, renal, neurologic, metabolic, pulmonary, gastrointestinal, hematologic abnormality, chronic hepatic disease or any other disease which in the judgment of the investigator would interfere with the study or confound the results. * Other active cancer disease. * Serum creatinine \> 1.5 mg/dL for males and \>1.4 mg/dL for females. * Female patient who are breastfeeding or have a positive pregnancy test at screening or at any time during the study. * Any acute cardiovascular event during the last 6 months prior to inclusion. * Symptomatic congestive heart failure with ejection fraction \< 30%. * Patient has prothrombin time/International Normalization Ration (PT/INR) or partial thromboplastin time (PTT) test results \> 1.3 UNL. * Hemoglobin ≤ 11 g/dL * Platelets \< 150,000 per microliter * White blood cell count\<3,000 x109/L and/or absolute neutrophils count \<1.5 x 109/L * Significant swallowing disorders. * History of small bowel surgery. * Any history of pelvic or abdominal radiation. * Pre-existing mal-absorption syndrome, irritable bowel syndrome or other clinical situation which could affect oral absorption. * Mental disorders. * Inability to give written informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse events and serious adverse events occurence | treatment end (day 60 or 90) |
Secondary
| Measure | Time frame |
|---|---|
| The primary efficacy endpoint of this study is Overall Response Rate (ORR) | treatment end (day 60 or 90) |
Other
| Measure | Time frame | Description |
|---|---|---|
| To estimate the duration of treatment to achieve response | 9 months | To estimate the duration of treatment needed to achieve response |
Countries
Israel
Outcome results
None listed